EAN 2024 | Repurposing MS and NMOSD treatments for CIDP

Alicja Kalinowska, MD, PhD, Poznan University of Medical Sciences, Poznań, Poland, discusses medications used for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) that have potential to be repurposed for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Anti-CD20 antibodies are one such group with strong rationale for repurposing, given the importance of B-cell pathology in CIDP. Complement inhibitors, which are very efficacious in treating NMOSD, are another group highlighted. Complement activation has a very important role in CIDP, like in NMOSD, and published case series have shown success with compliment inhibitors in autoimmune neuropathies. Lastly, cladribine, while not yet tested for CIDP, is believed to be a promising option. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.